发明名称 |
PHARMACEUTICAL COMBINATIONS |
摘要 |
A pharmaceutical combination comprising (a) an ALK inhibitor, or a pharmaceutically acceptable salt thereof, and (b) at least one HDMA-2/p53 receptor inhibitor or a pharmaceutically acceptable salt, or at least one BRaf inhibitor or a pharmaceutically acceptable salt, and optionally a pharmaceutically acceptable carrier, for simultaneous, separate or sequential administration; the uses of such combination in the treatment of cancer; and methods of treating a subject suffering from a proliferative disease comprising administering a therapeutically effective amount of such combination. |
申请公布号 |
EP3086810(A2) |
申请公布日期 |
2016.11.02 |
申请号 |
EP20140821861 |
申请日期 |
2014.12.19 |
申请人 |
NOVARTIS AG |
发明人 |
LI, FANG;WANG, HUI-QIN;HALILOVIC, ENSAR;LIANG, JINSHENG |
分类号 |
A61K45/06;A61K31/4025;A61K31/404;A61K31/435;A61K31/496;A61P35/00 |
主分类号 |
A61K45/06 |
代理机构 |
|
代理人 |
|
主权项 |
|
地址 |
|